Results 271 to 280 of about 126,887 (307)
Some of the next articles are maybe not open access.
Fertility post immune checkpoint blockade.
Journal of Clinical Oncology, 202312014 Background: Immune checkpoint blockade (ICB) is radically altering the treatment paradigm for a wide range of malignancies. Consequently, the proportion of ICB exposed pts will expand and the impact of ICB on fertility is of increasing importance. We sought to evaluate fertility outcomes post ICB exposure at our institution.
Martinique Ogle +7 more
openaire +1 more source
Combining chemotherapy and immune checkpoint blockade
Current Opinion in Urology, 2016Immune checkpoint blockade results in durable responses in a subset of patients with advanced urologic tumors. However, the majority of patients do not respond to single agent therapy raising the hypothesis that combination regimens may extend the benefits of immune checkpoint blockade to an even broader patient population.
Ana, Collazo-Lorduy, Matthew D, Galsky
openaire +2 more sources
Immune Checkpoint Blockade and Skin Toxicity Pathogenesis
Journal of Investigative Dermatology, 2022Immune checkpoint blockade has revolutionized the treatment of multiple tumor types, including melanoma and nonmelanoma skin cancers. The use of immune checkpoint blockade is curtailed by tissue toxicities termed immune-related adverse events (irAEs), which occur most quickly and most often in the skin.
Barbara Ma, Niroshana Anandasabapathy
openaire +2 more sources
DNA repair and immune checkpoint blockade response
Cancer Genetics, 2022Immune checkpoint blockade (ICB) has shown immense promise for treating patients with various cancer types, but its effectiveness relies on our ability to identify likely responders. Here, we examined the association between mutations in 25 core DNA repair genes and ICB outcomes in 6619 patients across 9 cancer types with advanced disease and MSK ...
Jimmy A. Guo +7 more
openaire +2 more sources
Double immune checkpoint blockade in advanced NSCLC
Critical Reviews in Oncology/Hematology, 2020Immunotherapy-based options for patients with advanced non-small cell lung cancer (NSCLC) are increasing at an unprecedented pace, carrying the promise to prolong survival of this deadly disease. To maximize responses and extend benefit to a larger portion of patients, immunotherapy combination strategies are currently under investigation, with chemo ...
Mariniello A. +3 more
openaire +3 more sources
Adjuvant immune checkpoint blockade revisited
The Lancet Oncology, 2023Sahar Barjesteh, van Waalwijk van Doorn-Khosrovani +6 more
openaire +2 more sources
Microbiome dynamics in immune checkpoint blockade
Trends in Endocrinology & MetabolismImmune checkpoint blockade (ICB) is one of the leading immunotherapies, although a variable extent of resistance has been observed among patients and across cancer types. Among the efforts underway to overcome this challenge, the microbiome has emerged as a factor affecting the responsiveness and efficacy of ICB.
Chae Won Kim +2 more
openaire +2 more sources
Immune checkpoint blockades therapy of melanoma
Science Bulletin, 2023Hong, Liu +3 more
openaire +2 more sources
Immune Checkpoint Blockade in Metastatic Urothelial Cancer
Journal of Clinical Oncology, 2017The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches.
openaire +2 more sources